All In Biotech

Drug Trial Radar · NCT01105091

Epoprostenol for Injection in Pulmonary Arterial Hypertension

A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Mar 2010

Primary completion

May 2011

Study completion Jul 2011

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with pulmonary arterial hypertension who are naïve to injectable prostanoid treatment and in need of such treatment. Approximately 30 patients from 8 U.S. clinical sites will be randomized to receive either ACT-385781A or Flolan (2:1 respectively) for 28 days of treatment.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • ACT-385781A (Actelion Epoprostenol)Drug

    per Prescribing Information

  • Flolan®Drug

    Per Prescribing Information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/MinTime frame: Day 1
  2. Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/MinTime frame: Day 1
  3. Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/MinTime frame: Day 1
  4. Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/MinTime frame: Day 1
  5. Six-minute Walk Distance (6MWD) - Baseline and Day 28Time frame: Baseline and 28 days (+3 days)
  6. Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28Time frame: From baseline to 28 days (+3 days)
  7. Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28Time frame: Baseline and 28 days
  8. Blood Pressure - Baseline and Day 28Time frame: Baseline and 28 days
  9. Heart Rate - Baseline and Day 28Time frame: Baseline and 28 days
  10. Body Weight - Baseline and Day 28Time frame: Baseline and 28 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.